Skip to main content
. 2022 Aug 25;28(24):5272–5279. doi: 10.1158/1078-0432.CCR-22-1183

Figure 2.

Figure 2. Response rates. A, CR+CRi in patients with poor-risk cytogenetics. B, CR+CRi in patients with intermediate-risk cytogenetics. C, Transfusion independence in patients with poor-risk cytogenetics. D, Transfusion independence in patients with intermediate-risk cytogenetics. E, MRD < 10−3 in patients with poor-risk cytogenetics. F, MRD <10−3 in patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; mut, mutated; wt, wild-type; Ven, venetoclax.

Response rates. A, CR+CRi in patients with poor-risk cytogenetics. B, CR+CRi in patients with intermediate-risk cytogenetics. C, Transfusion independence in patients with poor-risk cytogenetics. D, Transfusion independence in patients with intermediate-risk cytogenetics. E, MRD <10−3 in patients with poor-risk cytogenetics. F, MRD <10−3 in patients with intermediate-risk cytogenetics. Abbreviations: Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; mut, mutated; wt, wild-type; Ven, venetoclax.